Future research should focus on further unraveling the molecular mechanisms underlying the IL4I1-AhR signaling axis and developing targeted therapeutic strategies to modulate this pathway, thereby mitigating CRS progression and improving clinical outcomes. This evidence concerns the gene IL4I1 and congenital rubella syndrome.